Ghost Tree Capital’s vTv Therapeutics VTVT Stock Holding History

Ghost Tree Capital’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-5,000	Closed	-$966K	–	83
2016 Q4	$966K	Buy	+5,000	New	+$1.15M	0.23%	63

Other funds holding VTVT

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ghost Tree Capital's VTVT Position: Q1 2017 in Review

Ghost Tree Capital sold out of vTv Therapeutics (VTVT) in Q1 2017, closing a stake of 5,000 shares — an estimated $966K sold.

Ghost Tree Capital first reported a position in VTVT in Q4 2016 and held it in 1 quarter. The position peaked at $966K in Q4 2016. 41 funds tracked by Wall St. Rank hold VTVT as of Q1 2017.

Ghost Tree Capital reported no remaining vTv Therapeutics position as of Q1 2017 after selling out during the quarter.
Ghost Tree Capital sold 5,000 vTv Therapeutics shares in Q1 2017, an estimated $966K.
Ghost Tree Capital first reported a position in vTv Therapeutics in Q4 2016 and held it in 1 quarter.
Ghost Tree Capital's vTv Therapeutics position peaked at $966K in Q4 2016.
41 funds tracked by Wall St. Rank held vTv Therapeutics as of Q1 2017.

Based on Ghost Tree Capital's 13F filing for Q1 2017, filed 15 May 2017.